icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Pan-Genotypic Hepatitis C Treatment With Glecaprevir/Pibrentasvir Achieves Greatest Improvements in Quality-Adjusted Life-Years and Lifetime Risk Reductions in Liver-Related Morbidity and Mortality vs Standards of Care: A Cost-Utility Analysis
 
 
  Reported by Jules Levin
American Association for the Study of Liver Diseases (AASLD) Congress, October 20-24, 2017, Washington, DC, USACONCLUSIONS
 
Sammy Saab1, Helene Parise2, Suchin Virabhak2, Scott Johnson2, Brett Pinsky3, Yuri Sanchez Gonzalez31David Geffen School of Medicine, UCLA, Los Angeles, CA; 2Medicus Economics, LLC, Boston, MA; 3Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL

1027171

1027172

1027173

1027174

1027175

1027176

1027177

1027178

1027179

10271710